tVNS for Prader-Willi syndrome

This page is intended for UK healthcare professionals. Clinical information, including study-level data and stimulation parameters, is included.

The clinical context

Prader-Willi syndrome (PWS) is a rare, complex genetic neurodevelopmental disorder affecting approximately 1 in 15,000 to 25,000 births. It is caused by the absence of expression of paternally imprinted genes at chromosome 15q11.2-q13, arising through paternal deletion (65 to 75%), maternal uniparental disomy (20 to 30%), or imprinting defects (1 to 3%).

The condition follows a distinctive developmental trajectory driven primarily by hypothalamic dysfunction. The hallmark hyperphagia and the challenging behavioural features, including temper outbursts, obsessive-compulsive behaviours, skin picking, and anxiety, create a management challenge that current pharmacotherapy cannot adequately address.

The point that frames the clinical interest in tVNS is this: there is no approved pharmacological treatment that addresses the core features of PWS. For hyperphagia, environmental management remains the primary intervention. For temper outbursts, which are a leading cause of placement breakdown, restricted community access, and reduced quality of life, no targeted treatments exist. SSRIs have shown some benefit for compulsivity, and aripiprazole is reported as helpful in approximately 70% of cases, but neither is a targeted intervention.

The vagus nerve is centrally positioned in the pathways governing emotional regulation, autonomic function, appetite signalling, and inflammation, all of which are disrupted in PWS.

Neurobiological rationale

Autonomic dysfunction in PWS

PWS is associated with well-documented autonomic dysfunction characterised by diminished parasympathetic (vagal) activity. HRV analysis shows reduced vagal tone during both wakefulness and sleep. Cardiovascular autonomic testing reveals impaired heart rate responses to active standing (47% of children) and deep breathing (22%). These abnormalities exist independently of obesity.

Emotional regulation pathways

The vagus nerve has extensive projections from the NTS to the locus coeruleus (norepinephrine), amygdala, prefrontal cortex, and nucleus accumbens. VNS modulates the LC-norepinephrine system (regulating arousal, attention, and adaptive behaviour), enhances prefrontal-amygdala connectivity (relevant to emotional dysregulation), and shifts autonomic balance toward parasympathetic predominance.

Gut-brain axis and appetite

The vagus nerve carries afferent signals from gut-based nutrient sensors to the NTS, with onward projections to the hypothalamic arcuate and paraventricular nuclei. Satiety hormones stimulate vagal afferent firing, while ghrelin (markedly elevated in PWS from early childhood) suppresses it. Research has shown that taVNS augments the postprandial decline in plasma ghrelin levels in healthy subjects (Kozorosky et al., 2022).

However, the implanted VNS study in PWS (Manning et al., 2016) did not achieve clear improvements in hyperphagia. The appetite mechanism has not been demonstrated clinically in this population. The evidence supports tVNS for behavioural regulation, not appetite control.

Hypothalamic engagement

fMRI studies confirm that cymba conchae stimulation produces bilateral deactivation of the hypothalamus (Frangos et al., 2015). This is particularly relevant to PWS, where hypothalamic dysfunction is the central pathological feature.

Anti-inflammatory effects

PWS is associated with low-grade systemic inflammation independent of obesity: elevated CRP, IL-6, IL-18, IL-1beta, and TNF-alpha compared with both lean and adiposity-matched obese controls. The cholinergic anti-inflammatory pathway engaged by tVNS provides a potential mechanism for modulating this inflammatory milieu.

Clinical evidence

The published research on tVNS specifically for PWS comes from a single research group at the University of Cambridge (Professor Anthony Holland, Dr Katie Manning). The total published tVNS sample size is five individuals. Transparency about the stage of evidence is essential.

Manning et al. (2016): implanted VNS

Open-label case series, three adults with PWS, 12 months of surgically implanted VNS. Changes in eating behaviour were equivocal. However, two of three participants showed unanticipated consistent beneficial effects in maladaptive behaviour, temperament, and social functioning. Both responders asked to continue VNS and at informal follow-up eight years later reported continuing benefits.

This serendipitous finding shifted the research focus from appetite to behaviour.

Manning et al. (2019): transcutaneous VNS (pivotal study)

Five adults with PWS (all paternal deletion subtype, aged 22 to 41). tVNS via left cymba conchae using the NEMOS device, 4 hours daily for 12 months, followed by 1 month at 2 hours daily.

Four of five participants demonstrated statistically significant reductions in outburst frequency and severity (p < 0.05)
Improvements emerged after approximately 9 months
Reducing to 2 hours daily led to increased outbursts in responders, demonstrating a dose-response relationship
All four responders opted to continue treatment after the study
One participant experienced mild skin irritation (resolved). No serious adverse events.

The dose-response finding strengthens the case for a genuine treatment effect. The 9-month latency is consistent with neuroplasticity-driven mechanisms of VNS observed in other conditions.

This was a non-blind study with no sham control. Clinicians should understand this context when counselling patients and families.

Schmausser et al. (2024): physiological evidence

Same five participants, analysed using cardiac markers of circadian vagal activity. After 12 months of tVNS:

Circadian amplitudes of HRV and heart rate significantly higher at end of treatment vs baseline (p < 0.01)
Rhythm-adjusted mean of HRV significantly increased (p < 0.01); heart rate mean significantly decreased
Higher rhythm-adjusted mean HRV predicted lower number of emotional outbursts

This provided the first physiological evidence linking tVNS-induced autonomic changes to behavioural improvement in PWS.

VNS4PWS Phase 3 trial (ongoing)

NCT06144645. Randomised, double-blind, dose-ranging trial sponsored by the Foundation for Prader-Willi Research. Comparing two doses of tVNS over 9 months, followed by 3 months evaluating cessation effects, plus a 1-year open-label extension. Primary outcome: reduction in temper outbursts. Ages 10 to 40, genetically confirmed PWS. This will provide the first blinded, controlled data.

Stimulation parameters

Based on Manning et al. (2019):

Parameter	Value
Frequency	25 Hz
Pulse width	250 microseconds
Intensity	0.1 to 5.0 mA (set to detectable tingling)
Duration	4 hours daily
Duty cycle	30 seconds on / 30 seconds off
Site	Left cymba conchae
Treatment duration	Minimum 9 to 12 months

The dose-response finding (4 hours > 2 hours) suggests that a substantial daily stimulation duration may be necessary. The VNS4PWS Phase 3 trial is comparing intermittent vs continuous stimulation at 4 hours daily.

PWS-specific safety considerations

The general tVNS safety profile applies (no serious device-related adverse events were reported in the small published PWS study; the Instructions for Use list the fuller range of possible effects). PWS-specific considerations:

Skin picking: present in 55 to 97% of individuals. The ear electrode site is not a typical target, but clinicians should monitor. Regular skin inspection is advisable.
Compliance and routine: a 4-hour daily commitment is substantial, but once established the structured routine may suit the preference for predictability characteristic of PWS.
Cognitive considerations: mild to moderate intellectual disability is typical. In most cases a carer will manage the device.
Sensory sensitivity: some individuals have altered sensory processing. Start intensity low and increase gradually.
Contraindications (per the IFU): pregnancy; active implants (cardiac pacemaker, implanted vagus nerve stimulator, cochlear implant); cerebral shunt; sore, broken, or diseased skin at the electrode site. Cardiac arrhythmia warrants medical clearance first.

Practical guidance for UK clinicians

Candidate selection

Genetically confirmed PWS with frequent temper outbursts (the primary evidence-supported indication)
Published evidence covers adults aged 22 to 41; Phase 3 trial includes ages 10 to 40
A carer who can manage the device and treatment schedule
Willingness to commit to a minimum 9 to 12 month trial at 4 hours daily
Exclusions (per the IFU): pregnancy; active implants (pacemaker, implanted VNS, cochlear implant); cerebral shunt; sore, broken, or diseased skin at the site (cardiac arrhythmia warrants medical clearance)

Treatment initiation

Manning protocol: 25 Hz, 250 microsecond pulse width, 4 hours daily at the left cymba conchae
Titrate intensity gradually to detectable tingling (0.1 to 5.0 mA)
Introduce gradually over 1 to 2 weeks with clear visual schedules where appropriate
Maintain a behavioural diary (outburst frequency, duration, severity) from at least 4 weeks before starting

Monitoring

Behavioural diary at each review
Regular skin inspection at electrode site
Consider baseline and periodic HRV assessment (objective physiological marker)
Review at 3, 6, 9, and 12 months

Counselling families

In the published study, 4 of 5 adults achieved significant reduction in temper outbursts after approximately 9 months. This is encouraging but comes from a small, unblinded study.
The device is CE-marked specifically for PWS, a meaningful regulatory distinction for a condition with no approved pharmacological treatments for core behavioural features.
Benefits take a long time to develop. Manage expectations clearly at the outset.
tVNS does not currently have evidence for reducing hyperphagia. Its demonstrated benefit is in behavioural regulation.
A larger blinded trial (VNS4PWS) is underway and will provide more definitive evidence.

Regulatory status

The tVNS E device holds Class IIa certification under EU MDR 2017/745, and Prader-Willi syndrome is one of its approved indications. Its full set of approved indications, per the Instructions for Use, is epilepsy, depression, chronic migraine, and Prader-Willi syndrome.

There is no NICE guidance specific to tVNS for PWS, and no FDA clearance.

Key evidence gaps

Total published tVNS sample in PWS is five individuals from a single study.
No blinded, controlled data yet. VNS4PWS Phase 3 results are pending.
All participants had the paternal deletion subtype. Efficacy in UPD or imprinting defect subtypes is unknown.
Published data covers adults aged 22 to 41. Effects in younger populations untested (Phase 3 includes ages 10 to 40).
Hyperphagia not demonstrated clinically. The appetite mechanism is biologically plausible but unproven.
Longest follow-up is 13 months. Long-term durability and cessation effects unknown.
All studies from a single research centre. Independent replication is needed.

This page is based on evidence available up to April 2026. The VNS4PWS Phase 3 trial (NCT06144645) is currently recruiting, and its results will significantly update the evidence landscape.

tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.